Svizzera - Franċiż - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - vildagliptinum, metformini hydrochloridum - comprimés pelliculés - vildagliptinum 50 mg metformini hydrochloridum 500 mg, hydroxypropylcellulosum, magnésium stearas, Überzug: hypromellosum, e 171, macrogolum 4000, talc, e 172 (jaune) e 172 (rouge), pour compresso de la brume. - antidiabétique oral utilisé - synthetika

Svizzera - Franċiż - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - vildagliptinum, metformini hydrochloridum - comprimés pelliculés - vildagliptinum 50 mg metformini hydrochloridum 850 mg, hydroxypropylcellulosum, magnésium stearas, Überzug: hypromellosum, e 171, macrogolum 4000, talc, e 172 (jaune), pour compresso de la brume. - antidiabétique oral utilisé - synthetika

Svizzera - Franċiż - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - vildagliptinum, metformini hydrochloridum - comprimés pelliculés - vildagliptinum de 50,00 mg metformini hydrochloridum 1000.00 mg, hydroxypropylcellulosum, magnésium stearas, Überzug: hypromellosum, e 171, macrogolum 4000, talc, e 172 (jaune), pour compresso de la brume. - antidiabétique oral utilisé - synthetika

Unjoni Ewropea - Franċiż - EMA (European Medicines Agency)

novartis europharm limited - la vildagliptine, la metformine chlorhydrate de - diabète sucré, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Unjoni Ewropea - Franċiż - EMA (European Medicines Agency)

novartis europharm limited  - la vildagliptine, la metformine chlorhydrate de - diabète sucré, type 2 - les médicaments utilisés dans le diabète - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Unjoni Ewropea - Franċiż - EMA (European Medicines Agency)

novartis europharm limited - vildagliptine - diabète sucré, type 2 - les médicaments utilisés dans le diabète - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Unjoni Ewropea - Franċiż - EMA (European Medicines Agency)

novartis europharm limited - vildagliptine - diabète sucré, type 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 et 5. 1 pour les données disponibles sur différentes combinaisons).

Unjoni Ewropea - Franċiż - EMA (European Medicines Agency)

novartis europharm limited - vildagliptine - diabète sucré, type 2 - les médicaments utilisés dans le diabète - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 et 5. 1 pour les données disponibles sur différentes combinaisons).

Belġju - Franċiż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pi pharma - vildagliptine; chlorhydrate de metformine - comprimé pelliculé - 50 mg - 850 mg - vildagliptine 50 mg; chlorhydrate de metformine 850 mg - metformin and vildagliptin

Belġju - Franċiż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pi pharma - vildagliptine; chlorhydrate de metformine - comprimé pelliculé - 50 mg - 1000 mg - vildagliptine 50 mg; chlorhydrate de metformine 1000 mg - metformin and vildagliptin